{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:12:16Z","timestamp":1792188736941,"version":"4.4.0"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Virology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.coviro.2025.101472","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T06:16:32Z","timestamp":1751004992000},"page":"101472","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["State-of-the-art in oncolytic virotherapy using adenoviruses other than the commonly applied adenovirus type 5"],"prefix":"10.1016","volume":"72","author":[{"given":"Katrin","family":"Schr\u00f6er","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotta","family":"Fiege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna","family":"Bjelic-Radisic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6639-4888","authenticated-orcid":false,"given":"Anja","family":"Ehrhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coviro.2025.101472_bib1","doi-asserted-by":"crossref","unstructured":"Modrow\u00a0S, Truyen\u00a0U; Sch\u00e4tzl\u00a0H: Molekulare Virologie. 2022: p. 841.","DOI":"10.1007\/978-3-662-61781-6"},{"key":"10.1016\/j.coviro.2025.101472_bib2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0022-2836(85)90186-X","article-title":"The structure of the adenovirus capsid.\u00a0I. An envelope model of hexon at 6 A resolution","volume":"185","author":"Burnett","year":"1985","journal-title":"J Mol Biol"},{"key":"10.1016\/j.coviro.2025.101472_bib3","unstructured":"Human Adenovirus Working Group. 24th February 2025]; Available from: \u3008http:\/\/hadvwg.gmu.edu\u3009."},{"key":"10.1016\/j.coviro.2025.101472_bib4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1556\/EuJMI.4.2014.1.2","article-title":"Human adenovirus: viral pathogen with increasing importance","volume":"4","author":"Ghebremedhin","year":"2014","journal-title":"Eur J Microbiol Immunol"},{"key":"10.1016\/j.coviro.2025.101472_bib5","doi-asserted-by":"crossref","first-page":", 5140","DOI":"10.3390\/ijms22105240","article-title":"Adenovirus structure: what is new?","volume":"22","author":"Gallardo","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coviro.2025.101472_bib6","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.jiph.2022.09.001","article-title":"Molecular epidemiology, genetic diversity, and vaccine availability of viral acute gastroenteritis in the middle East and North Africa (MENA) region","volume":"15","author":"Elbashir","year":"2022","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.coviro.2025.101472_bib7","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/jnci\/djj111","article-title":"China approves world's first oncolytic virus therapy for cancer treatment","volume":"98","author":"Garber","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.coviro.2025.101472_bib8","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2174\/1568009618666171129221503","article-title":"Oncorine, the world first oncolytic virus medicine and its update in China","volume":"18","author":"Liang","year":"2018","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.coviro.2025.101472_bib9","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.274.5286.373","article-title":"An adenovirus mutant that replicates selectively in p53-deficient human tumor cells","volume":"274","author":"Bischoff","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.coviro.2025.101472_bib10","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/jnci\/95.9.652","article-title":"Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway","volume":"95","author":"Fueyo","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.coviro.2025.101472_bib11","doi-asserted-by":"crossref","first-page":"13207","DOI":"10.1128\/JVI.78.23.13207-13215.2004","article-title":"Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5","volume":"78","author":"Holterman","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2025.101472_bib12","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/sj.gt.3301959","article-title":"Efficient gene transfer into human CD34+ cells by an adenovirus type 35 vector","volume":"10","author":"Sakurai","year":"2003","journal-title":"Gene Ther"},{"key":"10.1016\/j.coviro.2025.101472_bib13","doi-asserted-by":"crossref","first-page":"8946","DOI":"10.1128\/jvi.71.11.8946-8951.1997","article-title":"Construction of an adenovirus type 7a E1A- vector","volume":"71","author":"Abrahamsen","year":"1997","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2025.101472_bib14","doi-asserted-by":"crossref","first-page":"8802","DOI":"10.1073\/pnas.91.19.8802","article-title":"An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3","volume":"91","author":"Bett","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.coviro.2025.101472_bib15","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s11262-017-1487-2","article-title":"Getting genetic access to natural adenovirus genomes to explore vector diversity","volume":"53","author":"Zhang","year":"2017","journal-title":"Virus Genes"},{"key":"10.1016\/j.coviro.2025.101472_bib16","first-page":"29","article-title":"Construction of adenovirus type 5 early region 1 and 4 virus mutants","volume":"130","author":"Groitl","year":"2007","journal-title":"Methods Mol Med"},{"key":"10.1016\/j.coviro.2025.101472_bib17","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3390\/v10100568","article-title":"Rapid construction of a replication-competent infectious clone of human adenovirus type 14 by Gibson Assembly","volume":"10","author":"Pan","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2025.101472_bib18","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01924-17","article-title":"Rapid cloning of novel rhesus adenoviral vaccine vectors","volume":"92","author":"Abbink","year":"2018","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2025.101472_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199563","article-title":"Seamless assembly of recombinant adenoviral genomes from high-copy plasmids","volume":"13","author":"Miciak","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2025.101472_sbref18","article-title":"ADEVO: proof-of-concept of adenovirus-directed EVOlution by random peptide display on the fiber knob","volume":"32","author":"Sallard","year":"2024","journal-title":"Mol Ther Oncol"},{"key":"10.1016\/j.coviro.2025.101472_bib21","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkv031","article-title":"Ad 2.0: a novel recombineering platform for high-throughput generation of tailored adenoviruses","volume":"43","author":"Muck-Hausl","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.coviro.2025.101472_bib22","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/nbt.2183","article-title":"Full-length RecE enhances linear-linear homologous recombination and facilitates direct cloning for bioprospecting","volume":"30","author":"Fu","year":"2012","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.coviro.2025.101472_bib23","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0076-6879(10)77008-7","article-title":"A recombineering pipeline to make conditional targeting constructs","volume":"477","author":"Fu","year":"2010","journal-title":"Methods Enzym"},{"key":"10.1016\/j.coviro.2025.101472_bib24","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1016\/j.celrep.2017.05.008","article-title":"An engineered virus library as a resource for the spectrum-wide exploration of virus and vector diversity","volume":"19","author":"Zhang","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.coviro.2025.101472_bib25","article-title":"Improved seamless mutagenesis by recombineering using ccdB for counterselection","volume":"42","author":"Wang","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.coviro.2025.101472_bib26","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1089\/hgtb.2018.044","article-title":"Novel vector construction based on alternative adenovirus types via homologous recombination","volume":"29","author":"Zhang","year":"2018","journal-title":"Hum Gene Ther Methods"},{"key":"10.1016\/j.coviro.2025.101472_bib27","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/nprot.2016.054","article-title":"RecET direct cloning and Redalphabeta recombineering of biosynthetic gene clusters, large operons or single genes for heterologous expression","volume":"11","author":"Wang","year":"2016","journal-title":"Nat Protoc"},{"key":"10.1016\/j.coviro.2025.101472_bib28","article-title":"High-throughput cloning and characterization of emerging adenovirus types 70, 73, 74, and 75","volume":"21","author":"Zhang","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coviro.2025.101472_bib29","doi-asserted-by":"crossref","first-page":"6839","DOI":"10.1128\/jvi.70.10.6839-6846.1996","article-title":"Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism","volume":"70","author":"Krasnykh","year":"1996","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2025.101472_bib30","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3390\/cancers11020198","article-title":"Rodents versus pig model for assessing the performance of serotype chimeric Ad5\/3 oncolytic adenoviruses","volume":"11","author":"Koodie","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.coviro.2025.101472_bib31","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41417-020-00226-z","article-title":"Ad5\/3 is able to avoid neutralization by binding to erythrocytes and lymphocytes","volume":"28","author":"Zafar","year":"2021","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.coviro.2025.101472_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.engmic.2024.100140","article-title":"Role of homologous recombination\/recombineering on human adenovirus genome engineering: not the only but the most competent solution","volume":"4","author":"Dawson","year":"2024","journal-title":"Eng Microbiol"},{"key":"10.1016\/j.coviro.2025.101472_sbref31","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-024-06839-6","article-title":"Nonclinical characterization of ICVB-1042 as a selective oncolytic adenovirus for solid tumor treatment","volume":"7","author":"Kato","year":"2024","journal-title":"Commun Biol"},{"key":"10.1016\/j.coviro.2025.101472_bib34","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1007\/s00535-012-0711-z","article-title":"Chimeric 5\/35 adenovirus-mediated Dickkopf-1 overexpression suppressed tumorigenicity of CD44(+) gastric cancer cells via attenuating Wnt signaling","volume":"48","author":"Wang","year":"2013","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.coviro.2025.101472_bib35","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.3390\/ijms19092694","article-title":"Targeting CD46 enhances anti-tumoral activity of adenovirus type 5 for bladder cancer","volume":"19","author":"Do","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.coviro.2025.101472_bib36","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.canlet.2011.03.021","article-title":"Enhanced antitumor efficacy of a novel fiber chimeric oncolytic adenovirus expressing p53 on hepatocellular carcinoma","volume":"307","author":"Chen","year":"2011","journal-title":"Cancer Lett"},{"key":"10.1016\/j.coviro.2025.101472_bib37","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.omtm.2020.06.010","article-title":"Transient chimeric Ad5\/37 fiber enhances NK-92 carrier cell-mediated delivery of oncolytic adenovirus type 5 to tumor cells","volume":"18","author":"Gao","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.coviro.2025.101472_bib38","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01849-20","article-title":"The fiber knob protein of human adenovirus type 49 mediates highly efficient and promiscuous infection of cancer cell lines using a novel cell entry mechanism","volume":"95,","author":"Baker","year":"2021","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2025.101472_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.128","article-title":"RGD-modifided oncolytic adenovirus exhibited potent cytotoxic effect on CAR-negative bladder cancer-initiating cells","volume":"6","author":"Yang","year":"2015","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.coviro.2025.101472_bib40","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma","volume":"36","author":"Lang","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coviro.2025.101472_sbref39","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.ymthe.2024.01.035","article-title":"Chimeric oncolytic adenovirus evades neutralizing antibodies from human patients and exhibits enhanced anti-glioma efficacy in immunized mice","volume":"32","author":"Shin","year":"2024","journal-title":"Mol Ther"},{"key":"10.1016\/j.coviro.2025.101472_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112393","article-title":"A PD-L1 tropism-expanded oncolytic adenovirus enhanced gene delivery efficiency and anti-tumor effects","volume":"137","author":"Mei","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.coviro.2025.101472_bib43","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-016-0121-5","article-title":"Phase I study with ONCOS-102 for the treatment of solid tumors \u2014 an evaluation of clinical response and exploratory analyses of immune markers","volume":"4","author":"Ranki","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.coviro.2025.101472_bib44","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/1078-0432.CCR-22-2046","article-title":"Pilot study of ONCOS-102 and pembrolizumab: remodeling of the tumor microenvironment and clinical outcomes in anti-PD-1-resistant advanced melanoma","volume":"29","author":"Shoushtari","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.coviro.2025.101472_bib45","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007552","article-title":"ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized phase 2 study investigating clinical outcomes and the tumor microenvironment","volume":"11","author":"Ponce","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.coviro.2025.101472_bib46","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.18632\/oncotarget.2901","article-title":"Immunological data from cancer patients treated with Ad5\/3-E2F-Delta24-GMCSF suggests utility for tumor immunotherapy","volume":"6","author":"Hemminki","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.coviro.2025.101472_bib47","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-024-03219-0","article-title":"Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors","volume":"43","author":"Jirovec","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.coviro.2025.101472_bib48","article-title":"Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma","volume":"6","author":"Monberg","year":"2025","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.coviro.2025.101472_sbref47","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-56482-w","article-title":"The oncolytic adenovirus TILT-123 with pembrolizumab in platinum resistant or refractory ovarian cancer: the phase 1a PROTA trial","volume":"16","author":"Block","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.coviro.2025.101472_bib50","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1128\/jvi.52.2.336-343.1984","article-title":"Adenovirus cyt+ locus, which controls cell transformation and tumorigenicity, is an allele of lp+ locus, which codes for a 19-kilodalton tumor antigen","volume":"52","author":"Subramanian","year":"1984","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2025.101472_bib51","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/cgt.2010.79","article-title":"Oncolytic adenovirus based on serotype 3","volume":"18","author":"Hemminki","year":"2011","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.coviro.2025.101472_bib52","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nm.2270","article-title":"Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14","volume":"17","author":"Wang","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2025.101472_sbref51","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1265717","article-title":"Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy","volume":"6","author":"Zafar","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.coviro.2025.101472_bib54","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002409","article-title":"Directed evolution generates a novel oncolytic virus for the treatment of colon cancer","volume":"3","author":"Kuhn","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.coviro.2025.101472_bib55","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.omto.2016.12.001","article-title":"OvAd1, a novel, potent, and selective chimeric oncolytic virus developed for ovarian cancer by 3D-directed evolution","volume":"4","author":"Kuhn","year":"2017","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.coviro.2025.101472_sbref54","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.omto.2021.01.015","article-title":"Efficient antitumor effects of a novel oncolytic adenovirus fully composed of species B adenovirus serotype 35","volume":"20","author":"Ono","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.coviro.2025.101472_bib57","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.18632\/oncotarget.26754","article-title":"An oncolytic adenovirus 11p vector expressing adenovirus death protein in the E1 region showed significant apoptosis and tumour-killing ability in metastatic prostate cells","volume":"10","author":"Wu","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.coviro.2025.101472_sbref56","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1158\/1535-7163.MCT-21-0240","article-title":"Novel group C oncolytic adenoviruses carrying a miRNA inhibitor demonstrate enhanced oncolytic activity in vitro and in vivo","volume":"21","author":"Doerner","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.coviro.2025.101472_bib59","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3390\/v17020162","article-title":"Ad6-based GM-CSF expressing vector displays oncolytic and immunostimulatory effects in an immunocompetent syrian hamster model of cholangiocarcinoma","volume":"17","author":"Zabelina","year":"2025","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2025.101472_bib60","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3390\/v12121399","article-title":"Species D adenoviruses as oncolytic viral vectors","volume":"12","author":"Bullard","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2025.101472_sbref59","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.omto.2022.03.007","article-title":"Development of a low-seroprevalence, alphavbeta6 integrin-selective virotherapy based on human adenovirus type 10","volume":"25","author":"Bates","year":"2022","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.coviro.2025.101472_bib62","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1038\/mt.2012.115","article-title":"Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer","volume":"20","author":"Hemminki","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/j.coviro.2025.101472_bib63","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-017-0277-7","article-title":"Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection","volume":"5","author":"Garcia-Carbonero","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.coviro.2025.101472_bib64","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010016","article-title":"First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironments","volume":"12","author":"Naing","year":"2024","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.coviro.2025.101472_bib65","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1089\/10430349950017725","article-title":"A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma","volume":"10","author":"Hallenbeck","year":"1999","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.coviro.2025.101472_bib66","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0304-3835(02)00017-4","article-title":"Antitumoral effects of recombinant adenovirus YKL-1001, conditionally replicating in alpha-fetoprotein-producing human liver cancer cells","volume":"180","author":"Kim","year":"2002","journal-title":"Cancer Lett"},{"key":"10.1016\/j.coviro.2025.101472_bib67","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/mt.2009.262","article-title":"A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors","volume":"18","author":"Nemunaitis","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.coviro.2025.101472_bib68","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ymthe.2006.01.010","article-title":"Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells","volume":"14","author":"Bauerschmitz","year":"2006","journal-title":"Mol Ther"},{"key":"10.1016\/j.coviro.2025.101472_bib69","first-page":"4200","article-title":"The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts","volume":"59","author":"Yu","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.coviro.2025.101472_bib70","first-page":"2559","article-title":"Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells","volume":"57","author":"Rodriguez","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.coviro.2025.101472_bib71","first-page":"1498","article-title":"Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy","volume":"59","author":"Yu","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.coviro.2025.101472_bib72","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/sj.gt.3301867","article-title":"Selective gene expression using a DF3\/MUC1 promoter in a human esophageal adenocarcinoma model","volume":"10","author":"Gupta","year":"2003","journal-title":"Gene Ther"},{"key":"10.1016\/j.coviro.2025.101472_bib73","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.molonc.2011.10.001","article-title":"Inhibitory effect of survivin promoter-regulated oncolytic adenovirus carrying P53 gene against gallbladder cancer","volume":"5","author":"Liu","year":"2011","journal-title":"Mol Oncol"},{"key":"10.1016\/j.coviro.2025.101472_bib74","doi-asserted-by":"crossref","DOI":"10.1186\/s13578-020-00485-1","article-title":"Efficacy of a novel double-controlled oncolytic adenovirus driven by the Ki67 core promoter and armed with IL-15 against glioblastoma cells","volume":"10","author":"Zhang","year":"2020","journal-title":"Cell Biosci"},{"key":"10.1016\/j.coviro.2025.101472_bib75","first-page":"2023","article-title":"Oncolytic adenoviruses armed with co-stimulatory molecules for cancer treatment","volume":"15","author":"Gryciuk","year":"1947","journal-title":"Cancers"},{"key":"10.1016\/j.coviro.2025.101472_bib76","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/nm952","article-title":"CD46 is a cellular receptor for group B adenoviruses","volume":"9","author":"Gaggar","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.coviro.2025.101472_bib77","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3390\/cells11050841","article-title":"A human in vitro model to study adenoviral receptors and virus cell interactions","volume":"11","author":"Tsoukas","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.coviro.2025.101472_bib78","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.virol.2004.04.001","article-title":"Adenovirus type 5 pseudotyped with adenovirus type 37 fiber uses sialic acid as a cellular receptor","volume":"324","author":"Cashman","year":"2004","journal-title":"Virology"},{"key":"10.1016\/j.coviro.2025.101472_bib79","doi-asserted-by":"crossref","first-page":"7909","DOI":"10.1128\/JVI.72.10.7909-7915.1998","article-title":"The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F","volume":"72","author":"Roelvink","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.coviro.2025.101472_bib80","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1490856","article-title":"CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy","volume":"7","author":"Zafar","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.coviro.2025.101472_bib81","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1089\/hum.2020.222","article-title":"Oncolytic adenovirus type 3 coding for CD40L facilitates dendritic cell therapy of prostate cancer in humanized mice and patient samples","volume":"32","author":"Zafar","year":"2021","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.coviro.2025.101472_bib82","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/OV.S155946","article-title":"Oncolytic adenovirus Ad657 for systemic virotherapy against prostate cancer","volume":"7","author":"Nguyen","year":"2018","journal-title":"Oncolytic Virother"},{"key":"10.1016\/j.coviro.2025.101472_bib83","doi-asserted-by":"crossref","first-page":"537","DOI":"10.21873\/anticanres.16190","article-title":"Treatment of human pancreatic cancers following local and systemic administration of oncolytic adenovirus serotype 35","volume":"43","author":"Ono","year":"2023","journal-title":"Anticancer Res"},{"key":"10.1016\/j.coviro.2025.101472_bib84","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3390\/v15010182","article-title":"Development of oncolytic vectors based on human adenovirus type 6 for cancer treatment","volume":"15","author":"Osipov","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.coviro.2025.101472_bib85","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0510-7","article-title":"A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)","volume":"7","author":"Machiels","year":"2019","journal-title":"J Immunother Cancer"}],"container-title":["Current Opinion in Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625725000227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879625725000227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T11:08:40Z","timestamp":1756379320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879625725000227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":85,"alternative-id":["S1879625725000227"],"URL":"https:\/\/doi.org\/10.1016\/j.coviro.2025.101472","relation":{},"ISSN":["1879-6257"],"issn-type":[{"value":"1879-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"State-of-the-art in oncolytic virotherapy using adenoviruses other than the commonly applied adenovirus type 5","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coviro.2025.101472","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101472"}}